GlassScriptPhysician profile
Austin Liu
NPI 1679735351
$12,748.00
in general payments reported to CMS, 2019-2025
24 companies · $6,373 in 2025
The $6,373 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $616 · 2021: $763 · 2022: $1,253 · 2023: $1,523 · 2024: $1,387 · 2025: $6,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,680 · Consulting Fee: $4,525 · Travel and Lodging: $76.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,679.87 |
| Consulting Fee | $4,525.00 |
| Travel and Lodging | $76.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $4,716.17 | 2025 | Libtayo |
| Janssen Biotech, INC. | $3,171.30 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,526.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,001.32 | 2019-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $893.21 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $322.95 | 2021-2025 | Ilumya |
| Leo Pharma INC. | $145.98 | 2021-2024 | Adbry |
| Incyte Corporation | $127.77 | 2022-2025 | Opzelura |
| Organon LLC | $126.20 | 2025 | Vtama |
| Ucb, INC. | $93.59 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $93.03 | 2025 | |
| Misonix INC | $87.34 | 2020-2021 | |
| Amgen INC. | $82.50 | 2020-2024 | Otezla |
| Lilly USA, LLC | $79.28 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Prugen, INC. Pharmaceuticals | $66.63 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $44.44 | 2025 | Theragenesis Wound Matrix |
| Organogenesis INC. | $36.34 | 2025 | Affinity |
| Biofrontera INC. | $25.60 | 2020 | |
| Allergan, INC. | $24.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.42 | 2022 | |
| Genentech USA, INC. | $19.40 | 2023 | Erivedge |
| Mayne Pharma Commercial LLC | $15.40 | 2019 | |
| Mimedx Group, INC. | $14.43 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.71 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.